Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Liver enzymes
Biotech
Inventiva pauses MASH study over patient's raised liver enzymes
Inventiva has paused enrolling new patients into a phase 3 trial of its lead liver disease drug after a participant experienced raised enzyme levels.
James Waldron
Feb 16, 2024 8:15am
Surrozen stops IBD program due to dose concerns and competition
Jan 18, 2024 9:55am
Third Harmonic shares sink as trial hit by raised liver enzymes
Dec 15, 2022 8:50am
Elevated liver enzymes force Centessa to drop another asset
Aug 10, 2022 9:34am
Sirtuin enzyme could point to new therapies for diabetes and obesity
Jan 29, 2018 10:25am
